Source comparison
TB-500 Research Flexibility Considerations: Protocol Comparison
Single high-dose protocol Day 1 post-injury 5–10mg total 15–25% improvement 6–8 weeks to baseline ROM Insufficient for sustained G-actin sequestration. Initial saturation without coverage during remodeling phase Multi-dose inflammatory window protocol Days 1,
This comparison does not assign a generated winner or score.
- Single high-dose protocol
- Day 1 post-injury
- 5–10mg total
- 15–25% improvement
- 6–8 weeks to baseline ROM
- Insufficient for sustained G-actin sequestration. Initial saturation without coverage during remodeling phase
- Multi-dose inflammatory window protocol
- Days 1, 3, 5 post-injury
- 2–5mg per dose
- 50–65% improvement
- 3–5 weeks to baseline ROM
- Gold standard for tendon/ligament research. Maintains G-actin sequestration throughout inflammatory cascade
- Delayed administration protocol
- Day 7+ post-injury
- 5–10% improvement
- 8–10 weeks to baseline ROM
- Minimal efficacy once fibroblast activation peaks. TB-500 cannot reverse established fibrotic scarring
- Weekly maintenance protocol
- Weekly for 4 weeks starting day 1
- 2–3mg per dose
- 30–40% improvement
- 5–7 weeks to baseline ROM
- Suboptimal. Dosing frequency too low to maintain therapeutic G-actin sequestration during peak inflammatory phase